Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders
- 783 Downloads
Current treatments for schizophrenia adequately treat the positive symptoms of schizophrenia but only modestly improve cognitive deficits. This review provides evidence for and against the use of selective 5-HT receptor drugs as cognition enhancing agents for schizophrenia and other disorders.
Pre-clinical and clinical literature concerned with the role of the serotonergic system in cognition and memory as it relates to schizophrenia is reviewed. Individual 5-HT receptor subtypes for which selective drugs are available that are likely to improve cognition are reviewed. Recommendations for clinical testing are proposed.
Results and conclusions
Four 5-HT receptor systems (5-HT1A, 5-HT2A, 5-HT4, 5-HT6) are highlighted as suitable targets for enhancing cognition and memory. Because many clinically available antipsychotic drugs already target 5-HT1A, 5-HT2A and 5-HT6 receptors, design of clinical trials will need to take into account the serotonergic pharmacology of concurrently administered antipsychotic medications. 5-HT1A partial agonists and 5-HT2A antagonists have shown modest effectiveness in improving cognition in schizophrenia. 5-HT6-selective compounds for cognition enhancement are in late-stage clinical trials, while 5-HT4 compounds have not yet been tested in humans for cognition enhancement.
For stand-alone therapy for enhancing cognition, 5-HT1A partial agonists, 5-HT2A antagonists, 5-HT4 partial agonists and 5-HT6 antagonists are all likely to induce at least modest improvement in cognition in schizophrenia. If “add-on therapy” is contemplated, antipsychotic drugs with weak affinities for serotonin receptors should be used to avoid confounds. It is likely that serotonergic drugs will soon be available as cognition enhancing medications for disorders other than schizophrenia (e.g. dementia).
KeywordsSchizophrenia Cognition 5-HT2A 5-HT1A 5-HT6 5-HT4 Serotonin
This work was supported by the NIMH Psychoactive Drug Screening Program (NO1MH80005) and KO2MH01366 to B.L.R.
- Aghajanian GK, Marek GJ (1997) Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells. Neuropharmacology 36:589–599Google Scholar
- Chen A, Muzzio IA, Malleret G, Bartsch D, Verbitsky M, Pavlidis P, Yonan AL, Vronskaya S, Grody MB, Cepeda I, Gilliam TC, Kandel ER (2003) Inducible enhancement of memory storage and synaptic plasticity in transgenic mice expressing an Inhibitor of ATF4 (CREB-2) and C/EBP proteins. Neuron 39:655–669PubMedGoogle Scholar
- Kraepelin E (1919) Dementia praecox and paraphrenia. re-issued by Thoemmes Continuum, Dorset, UKGoogle Scholar
- Lamirault L, Guillou C, Thal C, Simon H (2003) Combined treatment with galanthaminium bromide, a new cholinesterase inhibitor, and RS67333, a partial agonist of 5-HT4 receptors, enhances place and object recognition in young adult and old rats. Prog Neuropsychopharmacol Biol Psychiatry 27:185–195CrossRefPubMedGoogle Scholar
- Lindner MD, Hodges DB, Hogan JB, Orie AF, Corsa JA, Barten DM, Polson C, Robertson BJ, Guss VB, Gillman KW, Starrett Jr JE, Gribkoff VK (2003) An assessment of the effects of 5-HT6 receptor antagonists in rodent models of learning. J Pharmacol Exp Ther (in press)Google Scholar
- Moser PC, Bergis OE, Jegham S, Lochead A, Duconseille E, Terranova JP, Caille D, Berque-Bestel I, Lezoualc’h F, Fischmeister R, Dumuis A, Bockaert J, George P, Soubrie P, Scatton B (2002) SL65.0155, a novel 5-hydroxytryptamine(4) receptor partial agonist with potent cognition-enhancing properties. J Pharmacol Exp Ther 302:731–741CrossRefPubMedGoogle Scholar
- Potkin SG, Shipley J, Bera R, Carreon D, Fallon J, Alva G, Keator D (2001) Clinical and PET effects of M100907, a selective 5HT-2A receptor antagonist. Schizophr Res 49:242Google Scholar
- Poyurovsky M, Koren D, Gonopolsky I, Schneidman M, Fuchs C, Weizman A, Weizman R (2003) Effect of the 5-HT2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: an add-on, double-blind placebo-controlled study. Eur Neuropsychopharmacol 13:123–128CrossRefPubMedGoogle Scholar
- Renyi L, Evenden JL, Fowler CJ, Jerning E, Kelder D, Lake-Bakaar D, Larsson LG, Mohell N, Sallemark M, Ross SB (2001) The pharmacological profile of (R)-3,4-dihydro-N-isopropyl-3-(N-isopropyl-N-propylamino)-2H-1-benzopyran- 5-carboxamide, a selective 5-hydroxytryptamine(1A) receptor agonist. J Pharmacol Exp Ther 299:883–893PubMedGoogle Scholar
- Riemer C, Borroni E, Levet-Trafit B, Martin JR, Poli S, Porter RH, Bos M (2003) Influence of the 5-HT6 receptor on acetylcholine release in the cortex: pharmacological characterization of 4-(2-bromo-6-pyrrolidin-1-ylpyridine-4-sulfonyl)phenylamine, a potent and selective 5-HT6 receptor antagonist. J Med Chem 46:1273–1276CrossRefPubMedGoogle Scholar
- Roth BL (1994) Multiple serotonin receptors: clinical and experimantal aspects. Ann Clin Psychiatr 6:67–78Google Scholar
- Roth BL, Willins D, Kristiansen K, Kroeze W (1999) Activation is hallucinogenic and antagonism is therapeutic: role of 5-HT2A receptors in atypical antipsychotic drug actions. Neuroscientist 5:254–262Google Scholar
- Roth BL, Lopez E, Patel S, Kroeze W (2000) Multiplicity of serotonin receptors: useless diverse molecules or an embarrassment of riches? Neuroscientist 6:252–262Google Scholar
- Umbricht D, Vollenweider FX, Schmid L, Grubel C, Skrabo A, Huber T, Koller R (2003) Effects of the 5-HT2A agonist psilocybin on mismatch negativity generation and AX-continuous performance task: implications for the neuropharmacology of cognitive deficits in schizophrenia. Neuropsychopharmacology 28:170–181CrossRefPubMedGoogle Scholar
- Velligan DI, Miller AL (1999) Cognitive dysfunction in schizophrenia and its importance to outcome: the place of atypical antipsychotics in treatment. J Clin Psychiatry 60 Suppl 23:25–28Google Scholar
- Vilaro MT, Domenech T, Palacios JM, Mengod G (2002) Cloning and characterization of a novel human 5-HT4 receptor variant that lacks the alternatively spliced carboxy terminal exon. RT-PCR distribution in human brain and periphery of multiple 5-HT4 receptor variants. Neuropharmacology 42:60–73CrossRefPubMedGoogle Scholar
- Weiner DM, Burstein ES, Nash N, Croston GE, Currier EA, Vanover KE, Harvey SC, Donohue E, Hansen HC, Andersson CM, Spalding TA, Gibson DF, Krebs-Thomson K, Powell SB, Geyer MA, Hacksell U, Brann MR (2001) 5-hydroxytryptamine2A receptor inverse agonists as antipsychotics. J Pharmacol Exp Ther 299:268–276PubMedGoogle Scholar
- Wooley D, Shaw E (1954) A biochemical and pharmacological suggestion about certain mental disorders. Proc Natl Acad Sci U S A 40:228–231Google Scholar
- Xia Z, Hufeisen SJ, Gray JA, Roth BL (2003b) The PDZ-binding domain is essential for the dendritic targeting of 5-HT2A serotonin receptors in cortical pyramidal neurons in vitro. Neuroscience (in press)Google Scholar